{"preliminary_commentary":{"by_channel":{"x_thread":3,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NCT04176198","nct_id":"NCT04176198","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04176198. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"Arm 1: nuvisertib (TP-3654)","type":"EXPERIMENTAL"},{"description":null,"label":"Arm 2: nuvisertib (TP-3654) added on to ruxolitinib","type":"EXPERIMENTAL"},{"description":null,"label":"Arm 3: nuvisertib (TP-3654) in combination with momelotinib","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2030-04-30","type":"ESTIMATED"},"conditions":["Myelofibrosis"],"enrollment":{"count":240,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Nusivertib","otherNames":["TP-3654"],"type":"DRUG"},{"name":"Ruxolitinib","otherNames":["Jakafi"],"type":"DRUG"},{"name":"Momelotinib","otherNames":["Ojjaara"],"type":"DRUG"}],"last_update":"2026-10-02","lead_sponsor":"Sumitomo Pharma America, Inc.","official_title":"A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-3654) in Patients With Intermediate or High-Risk Primary or Secondary Myelofibrosis","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2027-04-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Determine the incidence of dose-limiting toxicities (DLTs)","timeFrame":"28 days"},{"measure":"Determine the incidence of treatment emergent adverse events","timeFrame":"From start of treatment to end of study"},{"measure":"Assess patients for any evidence of preliminary activity by determining the number of patients with ≥ 35% spleen volume reduction (SVR35)","timeFrame":"From start of treatment to end of study"}],"references":[],"start_date":{"date":"2019-12-16","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis","url":"https://clinicaltrials.gov/study/NCT04176198"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04176198"}